文献速递中医内科中医康复中药与中成药合理使用

华佗再造丸对缺血性中风恢复期神经功能及肢体运动恢复的影响

Effect of Huatuo Zaizao Pill on Neurological Function and Limb Motor Recovery in Ischemic Stroke Patients During Convalescence: An Open-Labelled, Randomized Controlled Trial.
PubMed 文献 · Chin J Integr Med · 2025-04-15

结果显示华佗再造丸组在改善MAS、NIHSS、FM和BI评分方面优于对照组(均P<0.05),血脂、不良事件及肝肾功能组间无显著差异(P>0.05)。结论认为华佗再造丸可缓解痉挛、改善神经功能及预后,但需更大样本和更长观察期进一步验证。

要点

  • 华佗再造丸联合常规治疗可改善缺血性中风恢复期患者的痉挛状态和神经功能。
  • 华佗再造丸组在MAS、NIHSS、FM和BI评分上均优于对照组(P<0.05)。
  • 两组血脂、不良事件及肝肾功能指标无显著差异(P>0.05)。

核心结论

  • 华佗再造丸可缓解缺血性中风恢复期患者的痉挛状态,并改善神经功能及预后。

研究设计与样本

  • 前瞻性、开放标签、随机对照试验,于2021年5月至2023年6月在中国中医科学院西苑医院神经内科招募缺血性中风患者。
  • 华佗再造丸组口服华佗再造丸8g每日三次联合常规治疗,对照组仅常规治疗,疗程12周。

主要发现

  • 主要结局MAS评分从基线至第6周和第12周的变化,华佗再造丸组较对照组显著改善(均P<0.05,意向性分析和符合方案分析均如此)。
  • 次要结局NIHSS、FM和BI评分从基线至第6周和第12周的变化,华佗再造丸组均显著优于对照组(均P<0.05)。
  • 治疗12周后,两组血脂指标、不良事件及肝肾功能异常无显著差异(P>0.05)。

关键数值与推荐

  • 华佗再造丸用法:口服8g,每日三次,联合常规治疗,疗程12周。
  • 主要结局为MAS评分从基线至第6周和第12周的变化。
  • 次要结局包括NIHSS、FM、BI评分从基线至第6周和第12周的变化,以及12周后血脂指标。

临床怎么用

  • 对于缺血性中风恢复期患者,可考虑在常规治疗基础上加用华佗再造丸8g每日三次,疗程12周以改善痉挛和神经功能。
  • 使用华佗再造丸期间需监测肝肾功能和不良事件,本研究显示其安全性良好。

局限性

  • 本研究为开放标签设计,样本量较小(完成研究72例),观察期12周。
  • 结论需在更大样本量和更长观察期的临床试验中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effects of Chinese patent medicine Huatuo Zaizao Pill (HTZZ) on neurological function and limb motor in ischemic stroke (IS) patients during convalescence. METHODS: This is a prospective, open-labelled, randomized controlled trial. Patients with IS were recruited from the Neurology Department of Xiyuan Hospital of China Academy of Chinese Medical Sciences from May 2021 to June 2023. Eligible participants were randomly assigned to the HTZZ (40 cases) or control group (40 cases) at a ratio of 1:1. The HTZZ group was treated with oral HTZZ (8 g, thrice daily) combined with conventional treatment, while the control group received only conventional treatment. The treatment duration was 12 weeks. The primary outcome was the change in Modified Ashworth Scale (MAS) score from baseline to week 6 and 12. Secondary outcomes included changes in scores of National Institute of Health Stroke Scale (NIHSS), Fugl-Meyer Assessment (FM), and Barthel Index (BI) from baseline to week 6 and 12, as well as lipid indices after 12 weeks. All adverse events (AEs) were recorded and liver and kidney indices were evaluated. RESULTS: A total of 72 patients completed the study (38 in the HTZZ group and 34 in the control group). Compared with the control group, the HTZZ group demonstrated significant improvements in MAS, NIHSS, FM, and BI scores following 6 and 12 weeks of treatment in both intent-to-treat and per-protocol analyses (all P<0.05). No significant differences were noted between groups in lipid indices, AEs, and liver and kidney dysfunction after 12 weeks (P>0.05). CONCLUSIONS: HTZZ alleviated spasticity and enhanced neurological function and prognosis of IS patients during convalescence. However, further evaluation of HTZZ's effect on IS outcomes is warranted in clinical trials with larger sample sizes and extended observation periods. (Trial registration No. NCT04910256).

来源:Chin J Integr Med,查看原文。版权归原作者所有。

引用

  1. Ding YQ, Zhao D, Chen X, et al. Effect of Huatuo Zaizao Pill on Neurological Function and Limb Motor Recovery in Ischemic Stroke Patients During Convalescence: An Open-Labelled, Randomized Controlled Trial. Chin J Integr Med. 2025. PMID: 40232598. doi:10.1007/s11655-025-3928-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。